Skip Nav Destination
Issues
15 May 2020
-
Cover Image
Cover Image
The cover shows a fluorescent image of GBM cells showing activation of NOTCH, visualized by red NICD staining, in cells adjacent to oHSV-infected cells seen in green. The white staining is F-actin. For details, see the article by Otani and colleagues on page 2381 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan; Sakar Wahby; Jennifer J. Gao; Laleh Amiri-Kordestani; Amna Ibrahim; Erik Bloomquist; Shenghui Tang; Yuan Xu; Jiang Liu; Wentao Fu; Pengfei Song; Bellinda L. King-Kallimanis; Sherry Hou; Yutao Gong; Shyam Kalavar; Soma Ghosh; Reena Philip; Kirsten B. Goldberg; Marc R. Theoret; Gideon M. Blumenthal; Paul G. Kluetz; Rajeshwari Sridhara; Richard Pazdur; Julia A. Beaver
Clinical Trial Brief Report
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P. Patel; Megan Othus; Young Kwang Chae; Francis J. Giles; Donna E. Hansel; Preet Paul Singh; Annette Fontaine; Manisha H. Shah; Anup Kasi; Tareq Al Baghdadi; Marc Matrana; Zoran Gatalica; W. Michael Korn; Jourdain Hayward; Christine McLeod; Helen X. Chen; Elad Sharon; Edward Mayerson; Christopher W. Ryan; Melissa Plets; Charles D. Blanke; Razelle Kurzrock
Clinical Trials: Targeted Therapy
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study
Michael J. Burke; Rumen Kostadinov; Richard Sposto; Lia Gore; Shannon M. Kelley; Cara Rabik; Jane B. Trepel; Min-Jung Lee; Akira Yuno; Sunmin Lee; Deepa Bhojwani; Sima Jeha; Bill H. Chang; Maria Luisa Sulis; Michelle L. Hermiston; Paul Gaynon; Van Huynh; Anupam Verma; Rebecca Gardner; Kenneth M. Heym; Robyn M. Dennis; David S. Ziegler; Theodore W. Laetsch; Javier E. Oesterheld; Steven G. Dubois; Jessica A. Pollard; Julia Glade-Bender; Todd M. Cooper; Joel A. Kaplan; Midhat S. Farooqi; Byunggil Yoo; Erin Guest; Alan S. Wayne; Patrick A. Brown
First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Ravi Vij; Rajneesh Nath; Daniel E.H. Afar; María-Victoria Mateos; Jesús G. Berdeja; Marc S. Raab; Andreas Guenther; Joaquín Martínez-López; Andrzej J. Jakubowiak; Xavier Leleu; Katja Weisel; Shekman Wong; Scott Gulbranson; James P. Sheridan; Anita Reddy; Bruno Paiva; Anil Singhal; Jesús F. San-Miguel; Philippe Moreau
Clinical Trials: Immunotherapy
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Changqing Xie; Austin G. Duffy; Gagandeep Brar; Suzanne Fioravanti; Donna Mabry-Hrones; Melissa Walker; Cecilia Monge Bonilla; Bradford J. Wood; Deborah E. Citrin; Elizabeth M. Gil Ramirez; Freddy E. Escorcia; Bernadette Redd; Jonathan M. Hernandez; Jeremy L. Davis; Billel Gasmi; David Kleiner; Seth M. Steinberg; Jennifer C. Jones; Tim F. Greten
Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
Robert A. Figlin; Nizar M. Tannir; Robert G. Uzzo; Scott S. Tykodi; David Y.T. Chen; Viraj Master; Anil Kapoor; Daniel Vaena; William Lowrance; Gennady Bratslavsky; Mark DeBenedette; Alicia Gamble; Ana Plachco; Marcus S. Norris; Joe Horvatinovich; Irina Y. Tcherepanova; Charles A. Nicolette; Christopher G. Wood; for the ADAPT study group
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
Ming Lu; Panpan Zhang; Yanqiao Zhang; Zhongwu Li; Jifang Gong; Jie Li; Jian Li; Yan Li; Xiaotian Zhang; Zhihao Lu; Xicheng Wang; Jun Zhou; Zhi Peng; Weifeng Wang; Hui Feng; Hai Wu; Sheng Yao; Lin Shen
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
James R. Berenson; Jennifer To; Tanya M. Spektor; Daisy Martinez; Carley Turner; Armando Sanchez; Matthew Ghermezi; Benjamin M. Eades; Regina A. Swift; Gary Schwartz; Shahrooz Eshaghian; Laura Stampleman; Robert A. Moss; Stephen Lim; Robert Vescio
Precision Medicine and Imaging
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Charu Aggarwal; Jeffrey C. Thompson; Austin L. Chien; Katie J. Quinn; Wei-Ting Hwang; Taylor A. Black; Stephanie S. Yee; Theresa E. Christensen; Michael J. LaRiviere; Benjamin A. Silva; Kimberly C. Banks; Rebecca J. Nagy; Elena Helman; Abigail T. Berman; Christine A. Ciunci; Aditi P. Singh; Jeffrey S. Wasser; Joshua M. Bauml; Corey J. Langer; Roger B. Cohen; Erica L. Carpenter
Shortened Leukocyte Telomere Length Associates with an Increased Prevalence of Chronic Health Conditions among Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort
Nan Song; Zhenghong Li; Na Qin; Carrie R. Howell; Carmen L. Wilson; John Easton; Heather L. Mulder; Michael N. Edmonson; Michael C. Rusch; Jinghui Zhang; Melissa M. Hudson; Yutaka Yasui; Leslie L. Robison; Kirsten K. Ness; Zhaoming Wang
Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Non–Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy
Melissa A. Frick; Steven J. Feigenberg; Samuel R. Jean-Baptiste; Louise A. Aguarin; Amberly Mendes; Chimbu Chinniah; Sam Swisher-McClure; Abigail Berman; William Levin; Keith A. Cengel; Stephen M. Hahn; Jay F. Dorsey; Charles B. Simone, II; Gary D. Kao
Translational Cancer Mechanisms and Therapy
Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition
Yoshihiro Otani; Ji Young Yoo; Samantha Chao; Joseph Liu; Alena Cristina Jaime-Ramirez; Tae Jin Lee; Brian Hurwitz; Yuanqing Yan; Hongsheng Dai; Joseph C. Glorioso; Michael A. Caligiuri; Jianhua Yu; Balveen Kaur
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Elena Ivanova; Mari Kuraguchi; Man Xu; Andrew J. Portell; Luke Taus; Irmina Diala; Alshad S. Lalani; Jihyun Choi; Emily S. Chambers; Shuai Li; Shengwu Liu; Ting Chen; Thanh U. Barbie; Geoffrey R. Oxnard; Jacob J. Haworth; Kwok-Kin Wong; Suzanne E. Dahlberg; Amir A. Aref; David A. Barbie; Magda Bahcall; Cloud P. Paweletz; Pasi A. Jänne
Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning
Seiya Yokoyama; Taiji Hamada; Michiyo Higashi; Kei Matsuo; Kosei Maemura; Hiroshi Kurahara; Michiko Horinouchi; Tsubasa Hiraki; Tomoyuki Sugimoto; Toshiaki Akahane; Suguru Yonezawa; Marko Kornmann; Surinder K. Batra; Michael A. Hollingsworth; Akihide Tanimoto
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Eileen M. Boyle; Cody Ashby; Ruslana G. Tytarenko; Shayu Deshpande; Hongwei Wang; Yan Wang; Adam Rosenthal; Jeffrey Sawyer; Erming Tian; Erin Flynt; Antje Hoering; Sarah K. Johnson; Michael W. Rutherford; Christopher P. Wardell; Michael A. Bauer; Charles Dumontet; Thierry Facon; Sharmilan Thanendrarajan; Carolina D. Schinke; Maurizio Zangari; Frits van Rhee; Bart Barlogie; David Cairns; Graham Jackson; Anjan Thakurta; Faith E. Davies; Gareth J. Morgan; Brian A. Walker
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.